Letrilan

Letrozole, the active ingredient in Letrilan, is an aromatase inhibitor presented as an oral tablet for oral use. It is used to treat estrogen receptor‑positive breast cancer in postmenopausal women and to induce ovulation in certain infertility protocols, acting by reducing estrogen synthesis.

GNH USA supplies Letrilan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory approvals across EU and other markets. The company ensures batch‑to‑batch consistency and adheres to international pharmacovigilance standards.

Letrilan (letrozole) is employed in hormonal pathways primarily for estrogen‑dependent conditions. - Estrogen receptor‑positive breast cancer in postmenopausal women: reduces tumor growth by lowering circulating estrogen levels. - Ovulation induction in infertility treatment: promotes follicular development by decreasing estrogen feedback on the hypothalamic‑pituitary axis.

Letrilan may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes - Joint or muscle pain - Nausea - Fatigue

Serious or Rare Side Effects: - Severe bone loss or osteoporosis - Elevated liver enzymes indicating hepatic injury - Deep vein thrombosis or pulmonary embolism

When prescribing Letrilan, clinicians should consider several safety measures. - Monitor bone health: assess baseline density and consider calcium/vitamin D supplementation. - Assess liver function: perform periodic hepatic enzyme tests. - Evaluate cardiovascular risk: watch for hypertension or lipid changes. - Avoid use in pregnancy: letrozole is contraindicated due to teratogenic risk. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Letrilan can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: may counteract letrozole effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations. - Tamoxifen: antagonistic mechanisms may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - Warfarin: letrozole may enhance anticoagulant effect; monitor INR. - Selective serotonin reuptake inhibitors: may increase risk of mood changes. - Antacids containing aluminum/magnesium: may affect absorption; separate dosing by at least 2 hours.